Membrane Lipid Peroxidation
A R T I C L E S
PLPC/PEPC or PLPC/PDPC co-oxidation experiments. (Figure
S6-S7, Supporting Information).
and some have been shown to have interesting and diverse
biological activities.14,17,49 Because of this, we are in the process
of defining the reaction pathways and describing the products
of 7-DHC peroxidation. The results of those studies will be
reported in due course.
Different ꢀ-fragmentation rate constants and propagation rate
constants to 9- and 13-peroxyl radicals also lead to differences
in the total amounts of 9- and 13-hydroperoxides (Figure S10,
Supporting Information). As indicated in Figure S10, more
9-products than 13-products were consistently observed in the
co-oxidation experiments of PLPC with nonoxidizable PCs,
PAPC, and 7-DHC, while they are about the same for oxidation
of linoleate in solution. Barclay and co-workers reported a
difference between 9- and 13-product formation in a study of
linoleate oxidation in micelles, more 13-product being formed
than 9.42 The different regioselectivities observed in bilayer and
micellar oxidations of linoleate are not readily explained but
the source of the selectivity must result from different exposures
of intermediate peroxyl radicals to the aqueous medium in the
micelle and bilayer environments.
Experimental Section
General Procedure for Calibration Experiments and
Co-Oxidation with Cholesterol in Liposomes. PLPC and nonre-
active PCs or cholesterol (in chloroform; [PC]final ) 50-80 mM)
were added to a 2 mL vial. The solution was dried by a flow of N2,
and was kept under vacuum for 10 min. PBS buffer (190 µL, 50
mM, pH ) 7.4) was then added and the mixture was sonicated for
10-20 s. The resulting milky suspension was incubated at 37 °C
for 10 min, which is followed by sonication for an additional 10-20
s. After addition of AIPH (10 µL, 0.02 M in PBS buffer), the milky
suspension was kept at 37 °C for 2 h. The oxidation reaction was
then quenched by adding BHT (100 µL, 0.1 M in ethanol) and
PPh3 (100 µL, 0.1 M in ethanol/CH2Cl2 ) 4/1). The mixture was
vortexed, and was then kept at room temperature for 30 min. Upon
addition of ethanol (500 µL) and LiOH (500 µL, 3 M), the resulting
mixture was stirred at 37 °C for 1 h, followed by acidification with
HCl (600 µL, 3 M). After extraction with hexanes (2 mL × 3), the
organic layers were combined and dried over MgSO4. The upper
clear solution was collected after centrifugation, and was blown
dry by a flow of N2. The residue remaining was dissolved in
benzene (300 + 100 µL) and was further stabilized by addition of
BHT in benzene (50 µL, 0.1 M). Samples were analyzed on normal
phase HPLC-UV (solvent, hexane/1.4% 2-propanol/0.1% acetic
acid; column 5 µm silica, 4.6 mm × 25 cm column, 1.0 mL/min;
detection UV 234 nm).
General Procedure for Clocking Experiments of PUFAs
and 7-DHC in Liposomes. One co-oxidation experiment of PLPC/
POPC/PAPC with nAA ) 0.1125 in the liposome is used as an
illustration: Chloroform solutions of PLPC (1.7 µmol), POPC (4.5
µmol) and PAPC (1.8 µmol) were added to a 2-mL vial and the
solution was dried by a flow of N2, after which it was kept under
vacuum for 10 min. Liposomes from this mixture were then
prepared by a procedure similar to that described in the previous
section. Thus, 95 µL of PBS buffer (50 mM, pH ) 7.4) was added
and the mixture was sonicated for an additional 10-20 s. The
resulting milky suspension was incubated at 37 °C for 10 min,
which was followed by another 10-20 s of sonication. After adding
the initiator AIPH (5 µL, 0.02 M in PBS buffer), the milky
suspension was kept at 37 °C for 1 h, and the reaction was quenched
by addition of BHT (100 µL, 0.1 M in ethanol) and PPh3 (150 µL,
0.1 M in ethanol/CH2Cl2 ) 4/1). The mixture was kept at room
temperature for 30 min and it was then hydrolyzed and worked up
in a procedure as described in the preceding section. Samples were
analyzed on normal phase HPLC-APCI-MS/MS (hexane/1.4%
2-propanol/0.1% acetic acid, 4.6 mm × 25 cm column, 5 µ, 1.0
mL/min). Selective reaction monitoring (SRM) was employed for
detection (m/z 295 f 195 for 13-substituted products 2b and 3a,
Implications
of
the
Exceptional
Reactivity
of
7-Dehydrocholesterol in Biology. The unusual reactivity of
7-DHC toward peroxyl radicals in solution and in bilayer
aggregates calls attention to the importance of this steroid in
biology. 7-DHC is the immediate biosynthetic precursor of
cholesterol,16,18,43,44 with the enzyme 7-dehydrocholesterol
reductase catalyzing the reduction of the C7dC8 double bond
of 7-DHC. The Smith-Lemli-Opitz syndrome (SLOS) is a
recessive disorder caused by mutations of the DHCR7 gene.
Impaired reductase activity for individuals having this syndrome
leads to a build-up of 7-DHC and lower than normal levels of
cholesterol in tissues and plasma.18,43,45-47 The experiments that
we report here show that 7-DHC is not just oxidatively unstable,
but it is one of the best chain-carrying molecules that has been
evaluated in free radical oxidation. This property of 7-DHC
should serve as an alert for the possibility of oxidative stress
whenever elevated levels of the compound are found, SLOS
being such an instance.48 Clearly, the compound should be added
to the list of lipids that are susceptible to peroxidation since
our studies show that 7-DHC is greater than ten times more
reactive than arachidonic acid, a polyunsaturated fatty acid that
is normally thought of as being particularly prone to peroxida-
tion. Products of 7-DHC peroxidation are also of interest because
of their potential as markers of oxidative stress in ViVo.
Furthermore, there are a host of oxysterol natural products17,48-63
(42) Barclay, L. R. C.; Crowe, E.; Edwards, C. D. Lipids 1997, 32, 237–
245.
(43) Haas, D.; Kelley, R. I.; Hoffmann, G. F. Neuropediatrics 2001, 32,
113–22.
(44) Waterham, H. R. Clin. Genet. 2002, 61, 393–403.
(45) Opitz, J. M.; Gilbert-Barness, E.; Ackerman, J.; Lowichik, A. Pediatr.
Pathol. Mol. Med. 2002, 21, 153–81.
(46) Kelley, R. I. AdV. Pediatr. 2000, 47, 1–53.
(47) Kelley, R. I.; Hennekam, R. C. J. Med. Genet. 2000, 37, 321–35.
(48) Gaoua, W.; Chevy, F.; Roux, C.; Wolf, C. J. Lipid Res. 1999, 40,
456–63.
(56) Mansoor, T. A.; Hong, J.; Lee, C. O.; Bae, S. J.; Im, K. S.; Jung,
J. H. J. Nat. Prod. 2005, 68, 331–336.
(49) Javitt, N. B. Curr. Opin. Lipidol. 2007, 18, 283–8.
(50) To¨ro¨csik, D.; Szanto, A.; Nagy, L. Mol. Aspects Med. 2009, electronic
ahead of print.
(57) Mansoor, T. A.; Lee, Y. M.; Hong, J.; Lee, C.-O.; Im, K. S.; Jung,
J. H. J. Nat. Prod. 2006, 69, 131–134.
(51) Akihisa, T.; Franzblau, S. G.; Tokuda, H.; Tagata, M.; Ukiya, M.;
Matsuzawa, T.; Metori, K.; Kimura, Y.; Suzuki, T.; Yasukawa, K.
Biol. Pharm. Bull. 2005, 28, 1117–1119.
(58) Yaoita, Y.; Amemiya, K.; Ohnuma, H.; Furumura, K.; Masaki, A.;
Matsuki, T.; Kikuchi, M. Chem. Pharm. Bull. 1998, 46, 944–950.
(59) Yaoita, Y.; Endo, M.; Tani, Y.; Machida, K.; Amemiya, K.; Furumura,
K.; Kikuchi, M. Chem. Pharm. Bull. 1999, 47, 847–851.
(60) Yaoita, Y.; Matsuki, K.; Iijima, T.; Nakano, S.; Kakuda, R.; Machida,
K.; Kikuchi, M. Chem. Pharm. Bull. 2001, 49, 589–594.
(61) Yaoita, Y.; Yoshihara, Y.; Kakuda, R.; Machida, K.; Kikuchi, M.
Chem. Pharm. Bull. 2002, 50, 551–553.
(62) Yue, J. M.; Chen, S. N.; Lin, Z. W.; Sun, H. D. Phytochemistry 2001,
56, 801–806.
(63) Albro, P. W.; Bilski, P.; Corbett, J. T.; Schroeder, J. L.; Chignell,
C. F. Photochem. Photobiol. 1997, 66, 316–325.
(52) Akihisa, T.; Nakamura, Y.; Tagata, M.; Tokuda, H.; Yasukawa, K.;
Uchiyama, E.; Suzuki, T.; Kimura, Y. Chem. BiodiVersity 2007, 4,
224–231.
(53) Ishizuka, T.; Yaoita, Y.; Kikuchi, M. Chem. Pharm. Bull. 1997, 45,
1756–1760.
(54) Kawagishi, H.; Katsumi, R.; Sazawa, T.; Mizuno, T.; Hagiwara, T.;
Nakamura, T. Phytochemistry 1988, 27, 2777–2779.
(55) Luo, X.; Li, F.; Shinde, P. B.; Hong, J.; Lee, C.-O.; Im, K. S.; Jung,
J. H. J. Nat. Prod. 2006, 69, 1760–1768.
9
J. AM. CHEM. SOC. VOL. 131, NO. 36, 2009 13043